Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

This Growth Stock Is Down 20% in the Great Rotation. I Think That's a Mistake.

View original at finance.yahoo.com
This Growth Stock Is Down 20% in the Great Rotation. I Think That's a Mistake. Artificial intelligence (AI) stocks have been leading the market higher for the past few years, but investors hit the emergency brake in 2026, sending many tech stocks suddenly tumbling…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The move into value and small-cap stocks is not necessarily a bad move with great bargains in the space

    60% confidence
  • Micron is the best bargain among tech stocks after the rotation

    60% confidence
  • Long-term HBM contracts will raise the floor on the DRAM market and make it less cyclical

    60% confidence
  • Investors are clearly questioning Micron's earnings sustainability despite strong current performance

    60% confidence
  • Micron issued robust guidance

    60% confidence
  • Micron's stock looks like a buy after this dip due to the new floor and secular growth trends in AI infrastructure

    60% confidence
  • All three big DRAM makers are working to sign longer-term contracts for HBM of between three and five years with base volume commitments

    60% confidence
  • The current DRAM cycle does not look like an ordinary DRAM cycle due to HBM structural drivers

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com